We are live on ! Find out more
CLRB icon

Cellectar Biosciences
CLRB

14 hedge funds and large institutions have $1.82M invested in Cellectar Biosciences in 2017 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

157,177% more capital inflows, than outflows

Capital inflows: $1.57M | Capital outflows: $1K

75% more funds holding

Funds holding: 8 → 14 (+6)

6.34% more ownership

Funds ownership: 2.7% → 9.04% (+6.3%)

Holders
14
Holders Change
+6
Holders Change %
+75%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
3
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$737K
2
Anson Funds Management
Anson Funds Management
Texas
+$567K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$134K
4
Virtu Financial
Virtu Financial
New York
+$58.1K
5
Citadel Advisors
Citadel Advisors
Florida
+$22.3K

Top Sellers

Rank Fund Capital Flow
1
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management
Wisconsin
-$1K

CLRB Hedge Fund Activity: Q4 2017 in Review

14 of the 4,420 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q4 2017, worth a combined $1.82M — up 288% from $469K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new CLRB positions and 0 closed out — a net gain of 6 holders — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $737K. The largest seller was Northwestern Mutual Wealth Management, cutting an estimated $1K.

  • 14 institutional investors held Cellectar Biosciences (CLRB) as of Q4 2017, up from 8 in Q3 2017.
  • Funds reported $1.82M of Cellectar Biosciences stock for Q4 2017, up 288% quarter-over-quarter.
  • 6 funds opened new Cellectar Biosciences positions in Q4 2017 and 0 closed out, a net change of +6 holders.
  • The largest Cellectar Biosciences buyer in Q4 2017 was Susquehanna International Group, an estimated $737K added.
  • The largest Cellectar Biosciences seller in Q4 2017 was Northwestern Mutual Wealth Management, an estimated $1K sold.

Based on aggregated 13F filings for Q4 2017.